| Lipids Management |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.87 |
| PCSK9 |
0 |
0.66 |
| Biologic Therapy |
0 |
0.52 |
| Monoclonal Antibody |
0 |
0.45 |
| Medicare |
0 |
0.38 |
| Coronary Artery Disease (CAD) |
0 |
0.32 |
| Cardiovascular disease |
0 |
0.3 |
| Grant |
0 |
0.3 |
| Familial Hypercholesterolemia |
0 |
0.21 |
| LDL Cholesterol |
0 |
0.99 |
| Adherence |
0 |
0.15 |
| Clinical Guidelines |
0 |
0.15 |
| Hypercholesterolemia |
0 |
0.15 |
| Statins |
0 |
0.15 |
| Patient Safety |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Adverse Effects |
0 |
0.08 |
| Diet |
0 |
0.08 |
| Disease Management |
0 |
0.08 |
| Endocrinology |
0 |
0.08 |
| Hand |
0 |
0.08 |
| Heart |
0 |
0.08 |
| Lipoproteins |
0 |
0.08 |
| Liver |
0 |
0.08 |
| New York |
0 |
0.08 |
| Salary and Compensation |
0 |
0.08 |